Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | PPIA | P62937 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241696 | 0.81 | CTSK (0.41) | CTSKMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7159422 | 0.80 | CTSK (0.56) | CTSKCTSSALDH1A1SMN1; SMN2 | |
| SCHEMBL7255553 | 0.80 | CTSK (0.47) | CTSKCTSSCTSLANPEP | |
| SCHEMBL7164798 | 0.79 | CTSK (0.39) | CTSKCTSSCTSLL3MBTL1NAMPT | |
| SCHEMBL7169622 | 0.79 | CTSK (0.45) | CTSKMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7163217 | 0.76 | CTSK (0.56) | CTSKCTSSCTSL | |
| SCHEMBL7165070 | 0.76 | CTSK (0.45) | CTSKCTSSCTSLANPEP | |
| SCHEMBL7338790 | 0.71 | CTSK (0.47) | CTSKCTSSCTSLMEN1ALDH1A1 | |
| SCHEMBL7249673 | 0.70 | KMT2A (0.45) | CTSKCTSSCTSLMEN1ALDH1A1 | |
| SCHEMBL7168553 | 0.68 | CTSK (0.42) | CTSKCTSSALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156280-A1 | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION, CORPORATION OF THE STATE OF DELAWARE | 2002-10-24 | — | — | US | claimed |
| US-6399604-B1 | ANXIETY, DOWN SYNDROME, SLEEP, COGNITIVE AND SEIZURE DISORDERS, AND OVERDOSE WITH BENZODIAZEPINE DRUGS | NEUROGEN CORPORATION | 2002-06-04 | — | — | US | claimed |
| US-6143760-A | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2000-11-07 | — | — | US | claimed |
| US-6646124-B2 | Gamma-aminobutyric acid (GABA) agonists, antagonists or inverse agonists; treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs | NEUROGEN CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20020156280-A1 | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION, CORPORATION OF THE STATE OF DELAWARE | 2002-10-24 | — | — | US | disclosed |
| US-6399604-B1 | ANXIETY, DOWN SYNDROME, SLEEP, COGNITIVE AND SEIZURE DISORDERS, AND OVERDOSE WITH BENZODIAZEPINE DRUGS | NEUROGEN CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-6331542-B1 | TREATING DISEASES CHARACTERIZED BY BONE LOSS OR EXCESSIVE CARTILAGE OR MATRIX DEGRADATION | SMITHKLINE BEECHAM CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-6143760-A | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156280-A1 | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands | GABRA4, GABRA1, GABRA2 | CTSK 4336/4885CTSS 2709/4885CTSL 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.